乌斯特基努马
阿达木单抗
医学
克罗恩病
维持疗法
内科学
疾病
克罗恩病
生物制剂
皮肤病科
胃肠病学
英夫利昔单抗
化疗
作者
Bruce E. Sands,Peter M. Irving,Timothy Hoops,James Izanec,Lei Gao,Christopher Gasink,Andrew Greenspan,Matthieu Allez,Silvio Danese,Stephen B. Hanauer,Vipul Jairath,Tanja Kuehbacher,James D. Lewis,Edward V. Loftus,Emese Mihály,Remo Panaccione,Ellen Scherl,О. Б. Щукина,William J. Sandborn
标识
DOI：10.1053/j.gastro.2021.06.040
摘要
Head-to-head trials are important to inform patient (pt) and physician choice. We studied the efficacy and safety of ustekinumab (UST) vs adalimumab (ADA) through 1 year in biologic-naïve pts with moderate-to-severe Crohn’s disease (CD).
科研通智能强力驱动
Strongly Powered by AbleSci AI
爱静静
zzzyyy
Singularity
乐乐乐乐乐乐
浅尝离白
8R60d8
shinysparrow
kento
愤怒的豆腐人
景辣条
寻道图强
竹筏过海
YifanWang
Ava
研友_ZAVbe8
鬼见愁
jyy
睡觉晒太阳
徐叽钰
不配.
皖公网安备34019202002308
